Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2018. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3695490016 | Product containing precisely rotigotine 250 microgram/1 hour prolonged-release transdermal patch (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3695492012 | Rotigotine 250 microgram/hour prolonged-release transdermal patch | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 4155191000052112 | rotigotin 250 mikrogram/timme, depåplåster | sv | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT Sweden NRC maintained module (core metadata concept) |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely rotigotine 250 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Is a | Rotigotine-containing product in transdermal dose form | false | Inferred relationship | Some | ||
| Product containing precisely rotigotine 250 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has concentration strength numerator unit | mcg | true | Inferred relationship | Some | 1 | |
| Product containing precisely rotigotine 250 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has basis of strength substance (attribute) | Rotigotine (substance) | true | Inferred relationship | Some | 1 | |
| Product containing precisely rotigotine 250 microgram/1 hour prolonged-release transdermal patch (clinical drug) | har nämnarvärde som visar koncentrationsstyrka | ett | false | Inferred relationship | Some | 1 | |
| Product containing precisely rotigotine 250 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has manufactured dose form | Prolonged-release transdermal patch (dose form) | true | Inferred relationship | Some | ||
| Product containing precisely rotigotine 250 microgram/1 hour prolonged-release transdermal patch (clinical drug) | har täljarvärde för koncentrationsstyrka | 250 | false | Inferred relationship | Some | 1 | |
| Product containing precisely rotigotine 250 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has concentration strength denominator unit | hour | true | Inferred relationship | Some | 1 | |
| Product containing precisely rotigotine 250 microgram/1 hour prolonged-release transdermal patch (clinical drug) | räkning av bas i aktiv ingrediens | ett | false | Inferred relationship | Some | ||
| Product containing precisely rotigotine 250 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has precise active ingredient | Rotigotine (substance) | true | Inferred relationship | Some | 1 | |
| Product containing precisely rotigotine 250 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Is a | Product containing only rotigotine in transdermal dose form (medicinal product form) | true | Inferred relationship | Some | ||
| Product containing precisely rotigotine 250 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Plays role | Antiparkinson therapeutic role | true | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets
FHIR